Corcept Therapeutics Incorporat

Historical 13F Holders

Symbol
CORT
CUSIP
218352102
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 218352102 since 12/18/2024, newest first.

Filer % of Class Filed
Renaissance Technologies LLC 13G/A Amendment 6
4.9% 8/13/2026
Event 4/1/2026
Ingalls & Snyder LLC 13G/A Amendment 17 6.8% 4/21/2026
Event 12/31/2025
Vanguard Group Inc 13G/A Amendment 9 0% 3/26/2026
Event 3/13/2026
Renaissance Technologies LLC 13G/A Amendment 5
5.5% 2/12/2026
Event 12/31/2025
BlackRock, Inc. 13G/A Amendment 4 10.9% 7/17/2025
Event 6/30/2025
BlackRock, Inc. 13G/A Amendment 3 12.7% 4/23/2025
Event 3/31/2025
Ingalls & Snyder LLC 13G/A Amendment 16 7.8% 2/21/2025
Event 12/31/2024
Joseph K. Belanoff 13G/A Amendment 4 6.3% 2/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 12 31.8 k $3.64 M
2026 Q2 453 92.0 M $7.27 B
2026 Q1 373 79.6 M $3.21 B
2025 Q4 426 76.9 M $2.68 B
2025 Q3 460 78.0 M $6.48 B
2025 Q2 455 79.7 M $5.93 B
2025 Q1 466 83.4 M $9.27 B
2024 Q4 401 84.4 M $4.25 B
2024 Q3 347 88.8 M $4.11 B
2024 Q2 309 90.8 M $2.95 B
2024 Q1 317 97.1 M $2.44 B
2023 Q4 296 86.8 M $2.82 B
2023 Q3 263 83.1 M $2.26 B
2023 Q2 232 81.5 M $1.81 B
2023 Q1 252 87.6 M $1.90 B
2022 Q4 256 86.7 M $1.76 B
2022 Q3 255 87.6 M $2.25 B
2022 Q2 236 85.1 M $2.03 B
2022 Q1 244 81.4 M $1.84 B
2021 Q4 234 80.8 M $1.60 B
2021 Q3 217 80.9 M $1.59 B
2021 Q2 216 80.5 M $1.77 B
2021 Q1 226 81.6 M $1.94 B
2020 Q4 251 86.4 M $2.26 B
2020 Q3 248 89.2 M $1.55 B
2020 Q2 247 89.6 M $1.51 B
2020 Q1 218 88.4 M $1.05 B
2019 Q4 224 90.5 M $1.10 B
2019 Q3 205 85.1 M $1.20 B
2019 Q2 205 86.5 M $964 M
2019 Q1 226 87.9 M $1.03 B
2018 Q4 241 92.6 M $1.24 B
2018 Q3 231 91.4 M $1.28 B
2018 Q2 237 87.9 M $1.38 B
2018 Q1 228 88.7 M $1.46 B
2017 Q4 205 88.9 M $1.61 B
2017 Q3 209 74.1 M $1.43 B
2017 Q2 167 69.8 M $824 M
2017 Q1 141 62.0 M $679 M
2016 Q4 142 55.0 M $399 M
2016 Q3 115 47.2 M $307 M
2016 Q2 112 45.7 M $250 M
2016 Q1 96 33.9 M $159 M
2015 Q4 101 34.2 M $170 M
2015 Q3 99 34.3 M $129 M
2015 Q2 82 32.5 M $195 M
2015 Q1 63 30.5 M $170 M
2014 Q4 52 28.8 M $86.3 M
2014 Q3 55 29.3 M $78.6 M
2014 Q2 63 30.0 M $83.9 M
2014 Q1 62 30.5 M $133 M